Warning! GuruFocus detected
1 Medium warning sign
with AZNN.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description

AstraZeneca PLC
NAICS : 325412
ISIN : US0463531089
Share Class Description:
MEX:AZNN: ADRCompare
Compare
Traded in other countries / regions
AZN.UKAZN.USAAZN.SwedenZEG.GermanyA1ZN34.BrazilAZN.ArgentinaAZN1.MexicoZEG.BulgariaAZNA.Austria IPO Date
2007-09-21Description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.39 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | 2.28 | |||||
Interest Coverage | 5.75 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.98 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.5 | |||||
3-Year EBITDA Growth Rate | 47.6 | |||||
3-Year FCF Growth Rate | 22.9 | |||||
3-Year Book Growth Rate | 3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 32.12 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.2 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76.44 | |||||
9-Day RSI | 62.23 | |||||
14-Day RSI | 61.05 | |||||
3-1 Month Momentum % | 16.64 | |||||
6-1 Month Momentum % | 0.33 | |||||
12-1 Month Momentum % | 35.82 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.93 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 196.62 | |||||
Days Sales Outstanding | 74.9 | |||||
Days Payable | 627.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.04 | |||||
Dividend Payout Ratio | 0.63 | |||||
3-Year Dividend Growth Rate | 3.9 | |||||
Forward Dividend Yield % | 2.04 | |||||
5-Year Yield-on-Cost % | 2.29 | |||||
Shareholder Yield % | 1.29 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.16 | |||||
Operating Margin % | 18.52 | |||||
Net Margin % | 13.03 | |||||
FCF Margin % | 13.59 | |||||
ROE % | 17.79 | |||||
ROA % | 6.8 | |||||
ROIC % | 9.31 | |||||
3-Year ROIIC % | -90.14 | |||||
ROC (Joel Greenblatt) % | 94.53 | |||||
ROCE % | 13.9 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 32.4 | |||||
Forward PE Ratio | 17.24 | |||||
PE Ratio without NRI | 32.4 | |||||
Shiller PE Ratio | 53.91 | |||||
Price-to-Owner-Earnings | 26.82 | |||||
PEG Ratio | 1.83 | |||||
PS Ratio | 4.22 | |||||
PB Ratio | 5.49 | |||||
Price-to-Free-Cash-Flow | 31.45 | |||||
Price-to-Operating-Cash-Flow | 19.29 | |||||
EV-to-EBIT | 24.06 | |||||
EV-to-Forward-EBIT | 16.96 | |||||
EV-to-EBITDA | 18.66 | |||||
EV-to-Forward-EBITDA | 13.51 | |||||
EV-to-Revenue | 4.65 | |||||
EV-to-Forward-Revenue | 4.54 | |||||
EV-to-FCF | 34.58 | |||||
Price-to-GF-Value | 0.91 | |||||
Price-to-Projected-FCF | 2.46 | |||||
Price-to-DCF (Earnings Based) | 2.81 | |||||
Price-to-DCF (FCF Based) | 1.2 | |||||
Price-to-Median-PS-Value | 0.93 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.64 | |||||
Earnings Yield (Greenblatt) % | 4.16 | |||||
FCF Yield % | 3.2 | |||||
Forward Rate of Return (Yacktman) % | 14.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AstraZeneca PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 1,015,558.984 | ||
EPS (TTM) (MXN) | 41.662 | ||
Beta | 0.05 | ||
3-Year Sharpe Ratio | 0.08 | ||
3-Year Sortino Ratio | 0.11 | ||
Volatility % | 33.21 | ||
14-Day RSI | 61.05 | ||
14-Day ATR (MXN) | 4.125738 | ||
20-Day SMA (MXN) | 1523.05 | ||
12-1 Month Momentum % | 35.82 | ||
52-Week Range (MXN) | 1111.46 - 1751.39 | ||
Shares Outstanding (Mil) | 3,100.33 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
AstraZeneca PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
AstraZeneca PLC Stock Events
Event | Date | Price (MXN) | ||
---|---|---|---|---|
No Event Data |
AstraZeneca PLC Frequently Asked Questions
What is AstraZeneca PLC(MEX:AZNN)'s stock price today?
The current price of MEX:AZNN is MXN1529.00. The 52 week high of MEX:AZNN is MXN1751.39 and 52 week low is MXN1111.46.
When is next earnings date of AstraZeneca PLC(MEX:AZNN)?
The next earnings date of AstraZeneca PLC(MEX:AZNN) is 2025-04-29.
Does AstraZeneca PLC(MEX:AZNN) pay dividends? If so, how much?
The Dividend Yield %  of AstraZeneca PLC(MEX:AZNN) is 2.04% (As of Today), Highest Dividend Payout Ratio of AstraZeneca PLC(MEX:AZNN) was 35.15. The lowest was 0.63. And the median was 1.65. The  Forward Dividend Yield % of AstraZeneca PLC(MEX:AZNN) is 2.04%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |